Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V9RU
|
|||
| Former ID |
DNC006862
|
|||
| Drug Name |
ENIPORIDE
|
|||
| Synonyms |
Eniporide; 176644-21-6; N-(diaminomethylene)-2-methyl-5-(methylsulfonyl)-4-(1H-pyrrol-1-yl)benzamide; N-Carbamimidoyl-2-methyl-5-(methylsulfonyl)-4-(1H-pyrrol-1-yl)benzamide; EMD-96785; UNII-7IGF9182QU; CHEMBL64360; 7IGF9182QU; Eniporide [INN]; C14H16N4O3S; N-(Diaminomethylene); AC1O5FJV; Eniporide(EMD96785); SCHEMBL6619621; CTK8C4436; UADMBZFZZOBWBB-UHFFFAOYSA-N; MolPort-035-675-643; KS-00000IZ2; EX-A1476; CZC25146; BCP09780; BDBM50058715; ANW-71932; 9260AA; ZINC13555902; AKOS024262733; AKOS016007503; DS-16493; AK-61121; AJ-64172
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cardiac arrhythmias [ICD-11: BC9Z; ICD-9: 427] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H16N4O3S
|
|||
| Canonical SMILES |
CC1=CC(=C(C=C1C(=O)N=C(N)N)S(=O)(=O)C)N2C=CC=C2
|
|||
| InChI |
1S/C14H16N4O3S/c1-9-7-11(18-5-3-4-6-18)12(22(2,20)21)8-10(9)13(19)17-14(15)16/h3-8H,1-2H3,(H4,15,16,17,19)
|
|||
| InChIKey |
UADMBZFZZOBWBB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 176644-21-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/hydrogen exchanger 1 (SLC9A1) | Target Info | Inhibitor | [2] |
| Sodium/hydrogen exchanger 3 (SLC9A3) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Cardiac muscle contraction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Regulation of actin cytoskeleton | ||||
| Thyroid hormone signaling pathway | ||||
| Salivary secretion | ||||
| Gastric acid secretion | ||||
| Pancreatic secretion | ||||
| Bile secretion | ||||
| Proteoglycans in cancer | ||||
| Proximal tubule bicarbonate reclamation | ||||
| Protein digestion and absorption | ||||
| Mineral absorption | ||||
| Pathway Interaction Database | Endothelins | |||
| RhoA signaling pathway | ||||
| ErbB1 downstream signaling | ||||
| Signaling mediated by p38-alpha and p38-beta | ||||
| Reactome | Hyaluronan uptake and degradation | |||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| G Protein Signaling Pathways | ||||
| Glycosaminoglycan metabolism | ||||
| Osteoclast Signaling | ||||
| SIDS Susceptibility Pathways | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010029) | |||
| REF 2 | Bicyclic acylguanidine Na+/H+ antiporter inhibitors. J Med Chem. 1998 Sep 10;41(19):3736-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.